Onderneming aTyr Pharma Inc Nasdaq
Aandelen
US0021201035
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Innovative Medicines
100,0
%
| 10 | 100,0 % | 0 | 100,0 % | -96,60% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 10 | 100,0 % | 0 | 100,0 % | -96,60% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Sanjay Shukla
CEO | Chief Executive Officer | 52 | 30-03-16 |
Jill Broadfoot
DFI | Director of Finance/CFO | 63 | 30-07-18 |
Lisa Carey
CTO | Chief Tech/Sci/R&D Officer | - | 01-06-15 |
Ashlee Dunston
IRC | Investor Relations Contact | - | 01-04-20 |
Peter Villiger
PRN | Corporate Officer/Principal | - | 01-05-16 |
Human Resources Officer | - | 24-12-21 | |
General Counsel | - | 06-10-21 | |
Leslie Nangle
PRN | Corporate Officer/Principal | - | - |
Nancy Krueger
LAW | General Counsel | 56 | 01-10-14 |
Andrew B. Cubitt
PRN | Corporate Officer/Principal | - | 01-09-11 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul Schimmel
FOU | Founder | 83 | 08-09-05 |
Tim Coughlin
CHM | Chairman | 57 | 10-04-17 |
John Clarke
BRD | Director/Board Member | 70 | 01-09-05 |
Sara Zaknoen
BRD | Director/Board Member | 65 | 25-05-21 |
Sanjay Shukla
CEO | Chief Executive Officer | 52 | 30-03-16 |
Jane Gross
BRD | Director/Board Member | 67 | 28-06-19 |
Svetlana Lucas
BRD | Director/Board Member | 52 | 28-06-19 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 69 010 940 | 67 228 938 ( 97,42 %) | 0 | 97,42 % |
Bedrijfsgegevens
aTyr Pharma, Inc.
10240 Sorrento Valley Road Suite 300
92121, San Diego
+858 731 8389
http://www.atyrpharma.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+28,05% | 48,16 mld. | |
-0,64% | 41,73 mld. | |
+43,45% | 41,03 mld. | |
-5,26% | 28,77 mld. | |
+10,80% | 25,59 mld. | |
-22,81% | 18,96 mld. | |
+8,07% | 12,92 mld. | |
+29,74% | 12,03 mld. | |
-2,27% | 11,77 mld. |